Omalizumab for the Treatment of Persistent Drug Induced Urticaria Elicited by Thienopyridines: A Case Report.

Q2 Medicine

Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry Pub Date : 2020-01-01 DOI:10.2174/1871523018666190522105055

Gianfranco Calogiuri, Eustachio Nettis, Alessandro Mandurino-Mirizzi, Elisabetta Di Leo, Luigi Macchia, Caterina Foti, Angelo Vacca, Nicholas G Kounis

引用次数: 2

Abstract

The anti-IgE Omalizumab may be helpful to treat clopidogrel hypersensitivity without stopping thienopyridine administration in patients requirining continuous antiplatellet therapy after coronary stent placement.

查看原文本刊更多论文

Omalizumab治疗噻吩吡啶引起的持续性药物性荨麻疹1例报告。

抗ige Omalizumab可能有助于在冠状动脉支架置入后需要持续抗血小板治疗的患者不停止噻诺吡啶给药的情况下治疗氯吡格雷过敏。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry Pharmacology, Toxicology and Pharmaceutics-Pharmacology

CiteScore

3.30

自引率

0.00%

发文量

期刊介绍： Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry aims to cover all the latest and outstanding developments in medicinal chemistry and rational drug design for the discovery of new anti-inflammatory & anti-allergy agents. Publishing a series of timely in-depth reviews written by leaders in the field covering a range of current topics, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments in the field.